Pulse Biosciences enters equity distribution agreement for up to $75 million at-the-market offering

Pulse Biosciences entered an equity distribution agreement with Mizuho to sell up to $75 million of common stock in an at-the-market offering.

Sales can be made from time to time at prevailing market prices, prices tied to market levels, or negotiated prices.

Mizuho will act as sales agent, earning up to a 3% commission on gross proceeds from shares sold.

The program uses the company’s effective Form S-3 shelf registration filed Feb. 19, 2026, effective Feb. 27, 2026.